His-tones are not ruth-less: A ruthenium anticancer agent, RAPTA-C, was found to associate with chromatin in cancer cells and to form stable, well-defined adducts in the nucleosome core at specific histone protein sites (see picture). This illuminates the macromolecular binding properties of this antimetastasis agent and indicates potential for developing metallodrugs for site-selective targeting of chromatin.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: